Developing therapeutic monoclonal antibodies and ADC's is a key focus of the pharmaceutical industry's R&D. The European Antibody Congress 2012 bought together senior level executives and opinion leaders from around the globe to further their knowledge and engage in discussion on a variety of topics relating to mAbs, ADC's and bispecifics. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Mark Glassy, Chief Executive Officer, Nascent Biologics, âCase study: how collaboration can lead to faster pipeline progression'.
This presentation focuses on:
Â· Outlining the background of Pritumumab; from antibody design to mechanism of action
Â· Evaluating the advances made through R&D and into preclinical trials
Â· Highlighting the problems encountered by a small biotech when taking a product into clinical trials
Are you interested in learning more and engaging in discussion on mAbs, ADC's, bispecifics and antibody biosimilars? Do you want to hear the most recent updates on mAbs/ADC's at the clinical stage? Do you want to network with senior executives and opinion leaders from truly international antibody pioneers? Take a look at the European Antibody Congress 2013.